ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
The positive prognostic impact of Bcl-xl and Bcl-2 in chemo-naive lung cancer patients depends on stage and histology Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Bcl-2, Bcl-xl, and pp32/PHAPI in resected non-small-cell lung cancer patients Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Antigen a in blood correlates with improved survival in resected NSCLC patients Source: Eur Respir J 2007; 30: Suppl. 51, 669s Year: 2007
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007
Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Telomerase activity in transthoracic fine needle biopsy specimens as a prognostic factor of survival in patients with non-small cell lung cancer (NSCLC) treated surgically or nonsurgically Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006
Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
The survival in elderly patients after resection of lung cancer Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007
Correlation between tumour size and survival in surgically treated patients with lung cancer, stage IA or B Source: Eur Respir J 2007; 30: Suppl. 51, 670s Year: 2007
Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005
Immunohistochemical study of intratumoral micro vessels in resected non-small cell lung carcinomas, N-status, pTNM-stage and survival period of the patients Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Factors influencing the early cancer relapse in patients with completely resected NSCLC Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008
Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013
The prognostic impact of stage and performance status on surgically resected non-small cell lung cancer Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012